Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Serum protein marker for tuberculosis drug resistance diagnosis and application thereof

A serum protein and marker technology, applied in the field of molecular biomedicine, can solve the problem of lack of drug-resistant TB serum diagnostic products

Active Publication Date: 2019-12-20
佛山市第四人民医院 +1
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no commercial drug-resistant TB serodiagnosis product

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Serum protein marker for tuberculosis drug resistance diagnosis and application thereof
  • Serum protein marker for tuberculosis drug resistance diagnosis and application thereof
  • Serum protein marker for tuberculosis drug resistance diagnosis and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0021] Based on the inventor's determination, a total of 4 cases of tuberculosis drug sensitivity (drug sensitivity, DS), 3 cases of monoresistance isoniazid (monoresistance isoniazide, MR-INH), 3 cases of monoresistance rifampin (monoresistance rifampin, MR-RFP) The proteomic results of the patient's serum samples were analyzed to identify the protein markers.

[0022] The relative abundance of differential proteins in the isoniazid-resistant and drug-sensitive groups is shown in Table 1, and the peptide profiles of the proteins are shown in Table 1. figure 1 shown.

[0023] Table 1 Relative abundance of differential proteins in isoniazid-resistant (MR-INH) and drug-sensitive (DS) groups

[0024]

[0025] Complement protein C4A (C4A), complement protein C4B (C4B), lactate dehydrogenase B (LDHB), keratin The content of protein 9 (KRT9) in sputum samples of tuberculosis isoniazid-resistant individuals was significantly higher than that of tuberculosis drug-susceptible indi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of a serum protein marker as a tuberculosis drug resistance diagnosis marker. The serum protein is at least one of a complement protein C4A (C4A), a complement protein C4B (C4B), lactic dehydrogenase B (LDHB), keratinose 9 (KRT9), alpha-2 macroglobulin (A2M), a blood coagulation factor XI (F11), serum iron transferrin (TF), immune globulin alpha-1 (IGHA1), immune globulin (IGHM), immune globulin J chain (JCHAIN), V1-47 proteins (IGLV1-47) and V4-31 proteins (IGHV4-31). According to the application, analysis is carried out according to serum proteins of individuals of different tuberculosis drug resistance types, and a new thought is provided for the targeted therapy of the tuberculosis drug resistance from the angle of the serum proteins.

Description

technical field [0001] The invention relates to the field of molecular biomedicine, in particular to a serum protein marker for tuberculosis drug resistance diagnosis and its application. Background technique [0002] Tuberculosis (Tuberculosis, TB) is a serious infectious disease caused by Mycobacterium tuberculosis, and it is still one of the main morbidity and fatal diseases of infectious diseases, especially in developing countries. Mycobacterium tuberculosis infection kills 8.6 million people every year. The WHO 2013 report showed that multidrug-resistant TB (MDR-TB) appeared in all countries and there were 40,000 new MDR-TB cases worldwide each year, accounting for 3.6% of new TB patients worldwide , and continues to grow. MDR-TB is the resistance of Mycobacterium tuberculosis to at least two first-line anti-tuberculosis drugs, isoniazid (INH) and rifampicin (RIF). of deaths could be prevented through early diagnosis and treatment, suggesting that the use of rapid a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/68
CPCG01N33/6893Y02A50/30
Inventor 林东子曾今诚王威林碧华余晓琳林炳耀刘新光周杰
Owner 佛山市第四人民医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com